Dr. Wei Teng is an Associate Professor of Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan. He received his MD degree from Taipei Medical University, school of medicine in 2008. He completed his postgraduate training course at the Department of Internal Medicine (2009-2012), Fellowship at the Department of Gastroenterology and Hepatology (2012-2014), Chang Gung Memorial Hospital, Linkou Medical Center and has been an Attending Physician in the Department of Gastroenterology and Hepatology since 2014. He received his Ph.D degree on 2022 from the Graduate School of Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University. Over the past 10 years, he has focused his scientific interests on the topics related to viral hepatitis including HBV for those patients in the gray zone of current HBV treatment guidelines, the outcome of post-DAA therapy for HCV patients, liver cirrhosis such as management of EV/GV, ascites and acute liver failure. Dr. Teng is dedicated in the field of hepatology and is specialized in the management and treatment of hepatocellular carcinoma. He also joined several global clinical trials including phase 1, 2 and 3 of HCC treatment. He is the first author of drafting HCC treatment guidelines of Taiwan Liver Cancer Association in 2024. He is also a member of Taiwan Association for the Study of Liver, European Association of Study of Liver and American Association of the Study of Liver Disease. He is a reviewer of several scientific journals such as Liver Cancer, Clinical Gastroenterology & Hepatology and Hepatology International and has published more than 50 peer-reviewed articles. Dr. Teng was an invited speaker in several international meetings discussing about HCC. Now his research interest focused on the immunologic study such as T cells/B cells/Macrophage in the tumor microenvironment and tried to find out the pivotal biomarkers predicting the outcome for HCC patients receiving immunotherapy.